Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.

Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, Maiorino L, Hetzel M, Leschinger M, Visseren-Grul C, Torri V.

J Clin Oncol. 2012 Jan 10;30(2):172-8. doi: 10.1200/JCO.2010.33.7089. Epub 2011 Nov 28.

PMID:
22124104
2.

Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B; Spanish Lung Cancer Group.

J Clin Oncol. 2010 Jul 1;28(19):3138-45. doi: 10.1200/JCO.2009.27.6204. Epub 2010 Jun 1.

PMID:
20516435
4.

Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer.

Davidov MI, Polotzky BE, Marenich AF, Orlov SV, Lazarev AF, Skryabina LS, Pavlushkov EV, Semenchenya VA, Brichkova OY, Karaseva VV.

Anticancer Drugs. 2011 Jul;22(6):569-75. doi: 10.1097/CAD.0b013e328342d50a.

PMID:
21487288
5.

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators.

J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61.

PMID:
14519751
6.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.

J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.

PMID:
18506025
7.

Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small-cell lung cancer.

Scagliotti GV.

Oncology (Williston Park). 2000 Jul;14(7 Suppl 4):15-9. Review.

8.

Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer.

Yamaguchi M, Takeo S, Suemitsu R, Matsuzawa H.

Cancer Chemother Pharmacol. 2010 May;66(1):107-12. doi: 10.1007/s00280-009-1139-x. Epub 2009 Oct 7.

PMID:
19809815
9.

Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.

Huisman C, Giaccone G, van Groeningen CJ, Sutedja G, Postmus PE, Smit EF.

Lung Cancer. 2001 Aug-Sep;33(2-3):267-75.

PMID:
11551422
10.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):777-84.

PMID:
14990632
11.

Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study.

De Pas T, Curigliano G, Veronesi G, Catalano G, Catania C, Jereczek-Fossa B, Orecchia R, Spaggiari L, de Braud F.

Bull Cancer. 2004 Sep 1;91(9):E273-7. Print 2004 Sep.

12.

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, et al.

J Natl Cancer Inst. 1994 May 4;86(9):673-80.

PMID:
8158698
13.

A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.

Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C, Franco Conte P.

Cancer. 2000 Oct 15;89(8):1714-9.

PMID:
11042565
14.

A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.

Grossi F, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, Ferraù F, Nardi M, Moscetti L, Boni L, Dondi D, Galligioni E.

Cancer Chemother Pharmacol. 2012 Feb;69(2):369-75. doi: 10.1007/s00280-011-1710-0. Epub 2011 Jul 21.

PMID:
21833588
15.

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A; NSCLC [non–small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group.

J Clin Oncol. 2012 Sep 1;30(25):3084-92. doi: 10.1200/JCO.2011.39.7646. Epub 2012 Jul 30.

PMID:
22851564
16.

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.

Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, Borsellino N, Pandolfo G, Durini E, Rinaldi M, Loizzi M, Gebbia N, Valenza R, Tirrito ML, Varvara F, Colucci G; Gruppo Ocologico Italia Meridionale.

Lung Cancer. 2003 Feb;39(2):179-89.

PMID:
12581571
17.

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.

Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ, de las Peñas R, Felip E, López-Vivanco G; Spanish Lung Cancer Group.

J Clin Oncol. 2003 Sep 1;21(17):3207-13.

PMID:
12947054
18.

Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.

Novello S, Falcone A, Crinò L, Rinaldi M, Nardi M, De Marinis F, Tonato M, Tibaldi C, Tinazzi A, Russo F, Grassivaro N, Scagliotti GV.

Lung Cancer. 2009 Dec;66(3):327-32. doi: 10.1016/j.lungcan.2009.02.009. Epub 2009 Mar 28.

PMID:
19329221
19.

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.

Binder D, Schweisfurth H, Grah C, Schäper C, Temmesfeld-Wollbrück B, Siebert G, Suttorp N, Beinert T.

Cancer Chemother Pharmacol. 2007 Jun;60(1):143-50. Epub 2006 Oct 10.

PMID:
17031643
20.

Supplemental Content

Support Center